Biocon Ltd

Biocon Ltd rose for a fifth straight session today. The stock is quoting at Rs 343.8, up 1.3% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.07% on the day, quoting at 25003.4. The Sensex is at 82230.01, down 0.12%. Biocon Ltd has added around 3.59% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has added around 2.33% in last one month and is currently quoting at 21633.2, up 1% on the day. The volume in the stock stood at 7.5 lakh shares today, compared to the daily average of 36.71 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 344.85, up 1.2% on the day. Biocon Ltd is up 11.77% in last one year as compared to a 10.98% gain in NIFTY and a 13.77% gain in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending March 25.Powered by Capital Market - Live

Rivaroxaban is a prescription medication used in the treatment of deep vein thrombosis and pulmonary embolism, to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation. The approval will further strengthen Biocon's portfolio of vertically integrated drug products,' the company said in a statement. Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. The company's consolidated net profit surged 154.24% to Rs 344.50 crore in Q4 FY25, compared with Rs 135.50 crore in Q4 FY24. Revenue from operations increased 12.76% YoY to Rs 4,417 crore during the period under review. The scrip rose 0.89% to currently trade at Rs 341.55 on the BSE. Powered by Capital Market - Live

Biocon announced that the 47th Annual General Meeting(AGM) of the company will be held on 8 August 2025.Powered by Capital Market - Live

Biocon announced that the Board of Directors of the Company at its meeting held on 8 May 2025, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 10%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Biocon rose 154.24% to Rs 344.50 crore in the quarter ended March 2025 as against Rs 135.50 crore during the previous quarter ended March 2024. Sales rose 12.79% to Rs 4358.10 crore in the quarter ended March 2025 as against Rs 3863.80 crore during the previous quarter ended March 2024. For the full year,net profit declined 0.90% to Rs 1013.30 crore in the year ended March 2025 as against Rs 1022.50 crore during the previous year ended March 2024. Sales rose 6.03% to Rs 15052.20 crore in the year ended March 2025 as against Rs 14195.80 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales4358.103863.80 13 15052.2014195.80 6 OPM %24.7423.63 -21.0422.64 - PBDT902.70734.80 23 3477.103105.60 12 PBT466.40327.80 42 1790.101536.80 16 NP344.50135.50 154 1013.301022.50 -1 Powered by Capital Market - Live

These agreements include key placements on national and regional formularies. Express Scripts added Yesintek to its National Preferred Formulary (NPF) effective 21 March 2025. Cigna included Yesintek on its commercial formulary starting 21 March 2025. UnitedHealthcare has added Yesintek to various formularies: commercial from 01 May 2025; managed Medicaid from 01 March 2025; and Medicare from 01 June 2025. CVS Health will include Yesintek beginning 01 July 2025, and Optum Rx will add it to its premium and select formularies from 01 July 2025. Furthermore, Yesintek has been selected on formularies by Navitus, Costco Health Solutions, MedImpact, Priority Health, University of Pittsburgh Medical Center (UPMC), and numerous other regional health plans. Notably, Blue Cross Blue Shield of Michigan (BCBSM), Florida Healthcare Plan, and several closed-door health systems have designated Yesintek as their exclusive ustekinumab product. BBL is also in the final stages of securing formulary agreements with additional commercial carriers, the company stated. Yesintek, a monoclonal antibody that inhibits IL-12 and IL-23 signaling associated with immune-mediated diseases, received U.S. FDA approval in December 2024. It is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Shreehas Tambe, CEO & managing director, Biocon Biologics, said: 'Yesintek (Ustekinumab kfce) represents an important milestone for Biocon Biologics, as this is the first product we have launched in the United States as a fully integrated biosimilars company. The strong adoption of Yesintek by payors in the U.S. reflects their confidence in our science, supply reliability, and commercial capability.' Biocon Biologics, a subsidiary of Biocon, is a fully integrated, global biosimilars company. It has commercialized eight biosimilars in key emerging markets and advanced markets. It has a pipeline of 12 biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. Biocon is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. Biocon is a biopharmaceutical company manufacturing APIs, and generic formulations. It is also involved in research and development. The company's consolidated net profit declined 96.2% to Rs 25.10 crore in Q3 FY25 as compared with Rs 660 crore in Q3 FY24. Net sales increased 6.3% to Rs 3773 crore in Q3 FY25. Powered by Capital Market - Live

'Raising of funds by way of issuance any instrument or security, including equity shares, non-convertible debt instruments along with warrants, any other convertible securities or any other eligible securities or any combination thereof by way of qualified institutions placement(s), rights issue, preferential allotment or private placement(s) and/or any combination thereof or any other method as may be permitted under applicable laws, and on such terms and conditions as may be considered appropriate by the board in its absolute discretion under applicable laws, for an aggregate amount of up to Rs 4,500 crore, in one or more tranches and/or one or more issuances, subject to the receipt of necessary approvals including approval of the shareholders of the company and other regulatory / statutory approvals,' it stated in exchange filing. Meanwhile, the company's board also approved to increase authorized share capital from existing Rs 625 crore divided into 125 crore equity shares of Rs 5 each to Rs 700 crore divided into 140 crore equity shares of Rs 5 each, subject to the receipt of necessary approvals including approval of the shareholders of the company and other regulatory / statutory approvals. Biocon is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. The company's consolidated net profit declined 96.2% to Rs 25.10 crore in Q3 FY25 as compared with Rs 660 crore in Q3 FY24. Net sales increased 6.3% to Rs 3773 crore in Q3 FY25. The counter rose 0.57% to end at Rs 335.85 on Wednesday, 23 April 2025.Powered by Capital Market - Live

The Board of Biocon at its meeting held on 23 April 2025 has approved raising of funds up to Rs 4,500 crore by way of issue of securities, in one or more tranches. The Board also approved increase in authorised share capital from Rs 625 crore to Rs 700 crore (dividend into 1,40,00,00,000 equity shares of Rs 5 each). Powered by Capital Market - Live

Biocon will hold a meeting of the Board of Directors of the Company on 23 April 2025.Powered by Capital Market - Live

Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for treating a range of ophthalmology conditions. The biosimilar references Regeneron's blockbuster drug EYLEA, a widely prescribed treatment in the U.S. for retinal diseases. As part of the settlement, Biocon Biologics and Regeneron agreed to dismiss ongoing litigation related to U.S. patent no. US11084865. This includes the pending appeal at the United States Court of Appeals for the Federal Circuit and the case in the U.S. District Court for the Northern District of West Virginia, Clarksburg Division. While the financial and commercial terms of the settlement remain confidential, the agreement enables Biocon Biologics to potentially commercialize Yesafili in the U.S. starting in the second half of 2026'or earlier, depending on certain conditions. The company has also secured a Canadian launch deal for Yesafili no later than 1 July 2025. Shreehas Tambe, CEO & managing director, Biocon Biologics, said: This settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality aflibercept biosimilar to patients and healthcare providers in the United States. As the first-to-file interchangeable biosimilar to Eylea, YESAFILI affirms our scientific strength and marks our strategic entry into Ophthalmology, expanding our footprint in the U.S. and advancing our mission to increase access to life-changing treatments. Biocon is an innovation-led global biopharmaceuticals company. On a consolidated basis, its net profit slumped 96.20% to Rs 25.10 crore while net sales rose 6.32% to Rs 3773 crore in Q3 December 2024 over Q3 December 2023. Powered by Capital Market - Live